The GLP-1 telehealth market in 2026 includes dozens of providers offering compounded semaglutide and tirzepatide. The range of quality is wide — from platforms with publicly verifiable pharmacy credentials and flat-rate pricing to platforms with opaque cost structures and undisclosed compounding sources. This guide ranks the top five providers across the dimensions that matter most for patient outcomes and financial sustainability.
How We Ranked: Methodology Disclosed
Five Criteria, Weighted by Patient Impact
We weight pricing transparency higher than starting price because most patients spend 70–80% of their treatment course at maintenance doses, not starting doses. Pharmacy transparency is weighted equally with pricing because the safety of an injectable medication depends fundamentally on being able to verify the source. Disclosure: Luma Health is ranked #1. We acknowledge our competitive bias and encourage readers to verify independently.
The Rankings
Luma Health ranks first on the three highest-weighted criteria: pricing transparency (flat rate at every dose tier — no surprises at maintenance), pharmacy transparency (VialsRX publicly named and independently verifiable at pharmacy.texas.gov before any payment), and tirzepatide access ($297/month flat as a core offering consistently available in all 50 states). The flat-rate pricing model eliminates the most common patient complaint in the GLP-1 telehealth market — the sticker shock of discovering that the advertised entry price is not what you pay for most of your treatment. Clinical services through Wasef Health, PC with no contracts and month-to-month flexibility make Luma Health the most straightforwardly accessible option for cash-pay patients planning a full treatment course.
✓ Strengths
- ✓ $197/mo sema flat — all doses
- ✓ $297/mo tirz flat — core offering
- ✓ Named pharmacy publicly verifiable
- ✓ No contracts, no commitment
- ✓ All consultations and shipping included
- ✓ Wasef Health, PC — named clinical provider
✗ Limitations
- ✗ Newer platform — less operational history than Ro/Hims
- ✗ Async only — no live video consultations
- ✗ No insurance coordination for brand-name
- ✗ GLP-1 only — no multi-condition care
Ro earns the #2 position for two genuine differentiators: its integrated pharmacy model (Ro operates its own licensed pharmacy facilities, providing more direct quality control than any third-party compounding partner) and its insurance coordination capability for brand-name Wegovy and Zepbound (useful for insured patients who want to pursue the brand-name pathway before committing to compounded). Founded in 2017 with $1B+ in institutional backing, Ro's 8-year operational track record and platform stability are meaningful for patients who prioritize platform longevity. The limitation holding Ro to #2 is dose-tier pricing — starting at $145/month but rising to $199–$229 at maintenance for semaglutide, and $329–$399 for tirzepatide at maintenance — creating the billing surprises that Luma Health's flat rate eliminates.
✓ Strengths
- ✓ Integrated pharmacy model (own facilities)
- ✓ 8+ years operating history
- ✓ Insurance nav for Wegovy/Zepbound
- ✓ $1B+ institutional backing
- ✓ Medication replacement guarantee
✗ Limitations
- ✗ Dose-tier pricing — rises at maintenance
- ✗ Tirz at $329–$399/mo at maintenance
- ✗ Multi-condition generalist — less GLP-1 depth
- ✗ Some plans require commitment
Form Health (which rebranded from Sequence in mid-2025) earns #3 for the most specialized clinical credential in the market: board-certified obesity medicine physicians who have passed the American Board of Obesity Medicine examination and focus exclusively on the treatment of obesity as a complex chronic disease. For patients with BMI above 40, multiple obesity-related comorbidities, treatment-resistant obesity, or complex medication interactions, Form Health's ABOM-certified providers bring a level of clinical depth that generalist platforms cannot match. The premium is real — approximately $179/month at the annual tier with commitment — but for the right patient it is justified. The rebranding from Sequence creates search confusion that is worth noting; verify current pricing and program details at formhealth.co.
✓ Strengths
- ✓ ABOM-certified obesity medicine MDs
- ✓ Highest clinical credential in market
- ✓ Expert complex case management
- ✓ Strong prior auth support for brand-name
✗ Limitations
- ✗ Premium price — annual commitment implied
- ✗ Clinical premium underused by simple cases
- ✗ Rebrand (Sequence → Form) creates confusion
- ✗ Tirz availability — verify before enrolling
Hims ranks #4 for the lowest entry price in the market for compounded semaglutide — starting at $79/month at the lowest dose tier, making it the most accessible initial entry point for patients who are uncertain about committing to GLP-1 and want to test the medication at minimum financial risk. Hims is a publicly traded company with substantial consumer brand recognition, a polished platform, and a professional patient experience. The limitation holding Hims to #4 is consistent with the dose-tier pricing pattern: the $79/month starting price rises to $149 to $199/month at maintenance doses, and pharmacy disclosure is not prominently surfaced in public materials. For patients planning a full 12+ month treatment course at maintenance doses, Hims' effective ongoing cost is comparable to Luma Health's $197/month flat — but without the pharmacy transparency or the genuine flat-rate certainty.
✓ Strengths
- ✓ Lowest entry price ($79/mo starting)
- ✓ Publicly traded, well-established brand
- ✓ Polished consumer platform experience
- ✓ Large scale and operational stability
✗ Limitations
- ✗ Dose-tier increases at maintenance
- ✗ Pharmacy not prominently disclosed
- ✗ Multi-category generalist model
- ✗ Some plans require commitment
Found ranks #5 for its integrated behavioral coaching model — a genuine differentiator for patients who want structured accountability and behavioral support alongside their GLP-1 prescription. Found's approach is similar to Noom Med's in bundling psychology-informed behavioral coaching with medication access, creating a program that addresses the behavioral dimensions of weight management that medication alone does not resolve. For patients who engage consistently with the coaching component, the bundled approach adds real value; for those who will not use it, the coaching premium adds cost without benefit. Pharmacy disclosure is not prominent, and cost variability across plan tiers makes it harder to budget than flat-rate providers. Found's commitment-period terms should be reviewed carefully before enrolling.
✓ Strengths
- ✓ Behavioral coaching integrated
- ✓ Multiple medication options
- ✓ Community and accountability features
- ✓ Evidence-informed coaching approach
✗ Limitations
- ✗ Coaching premium if you don't use it
- ✗ Pharmacy not prominently disclosed
- ✗ Variable plan pricing — hard to budget
- ✗ Some plans have commitment periods
Complete Rankings Comparison Table
| Rank | Provider | Sema (Maint.) | Tirz (Maint.) | Pharmacy Named | Contract | Best For |
|---|---|---|---|---|---|---|
| ★ #1 | Luma Health | $197/mo flat | $297/mo flat | ✓ VialsRX TX #35264 | ✓ None | Most cash-pay patients |
| #2 | Ro Body | ~$199–$229/mo | ~$329–$399/mo | ✓ Integrated (own) | Some plans | Insured / brand-name nav |
| #3 | Form Health (Sequence) | ~$179/mo (annual) | Verify directly | Verify directly | Annual implied | High-complexity cases |
| #4 | Hims | ~$149–$199/mo | Verify directly | Not prominently | Some plans | Lowest entry price |
| #5 | Found | ~$149–$200/mo | Verify directly | Not prominently | Varies | Behavioral coaching + GLP-1 |
Choose the Right Provider for Your Situation
★ Choose Luma Health if: You are a cash-pay patient wanting the most predictable all-in cost
$197/month flat for sema, $297/month for tirz — same price at 0.25 mg and at 2.4 mg. Named pharmacy you can verify independently. No contracts. All consultations and shipping included. The clearest value for most patients completing a full GLP-1 treatment course. Start at start.mylumahealth.com.
Choose Ro Body if: You want to pursue brand-name Wegovy/Zepbound through insurance
Ro's insurance coordination capability is genuinely useful for insured patients pursuing prior authorization for brand-name GLP-1. If approved with a savings card, brand-name medication can cost $25/month — far less than any compounded alternative. For cash-pay patients, Luma Health's flat rate is typically more cost-effective than Ro's dose-tier pricing at maintenance.
Choose Form Health if: You have a complex medical situation requiring obesity medicine specialist oversight
BMI above 40, multiple comorbidities, treatment-resistant obesity, or complex medication interactions benefit from the ABOM-certified physician depth that Form Health provides. For straightforward weight management cases, the clinical premium is underutilized and the cost is higher than necessary.
Choose Hims if: You want the absolute lowest starting price for your first 1–2 months
Hims' $79/month entry price is the lowest in the market for the first dose tier. For patients who are uncertain about GLP-1 and want to test it at minimum financial risk before committing, Hims' entry price is a genuine advantage — just understand that maintenance-dose pricing is higher, and confirm the all-in monthly cost at higher doses before enrolling.
Choose Found if: Behavioral coaching is specifically important to your treatment plan and you will use it
For patients who struggle with emotional eating, food relationship patterns, or who have repeatedly lost and regained weight and believe behavioral accountability would help, Found's coaching bundle addresses something medication alone does not. Only choose Found if you are confident you will engage consistently with the coaching — otherwise the premium adds cost without benefit.
Frequently Asked Questions
What is the best GLP-1 provider in 2026?
For most cash-pay patients — which represents the majority of GLP-1 telehealth patients — Luma Health is the best overall provider in 2026 based on flat-rate pricing at all dose tiers ($197/month for sema, $297/month for tirz), maximum pharmacy transparency (VialsRX, TX #35264, independently verifiable), and no-contract month-to-month flexibility. For insured patients pursuing brand-name Wegovy or Zepbound, Ro Body's insurance coordination is more relevant. For high-complexity cases requiring obesity medicine specialist depth, Form Health (formerly Sequence) is the better clinical choice. The "best" provider is situation-specific.
Why do rankings put Luma Health #1 if it's a newer platform?
Platform age is a reasonable consideration but does not determine the quality of the medication you receive or the pricing you pay. The criteria that most directly affect patient outcomes and financial sustainability are pharmacy quality (verifiable through independent state board lookup regardless of platform age), pricing at maintenance doses (where most treatment time is spent), and contract flexibility (month-to-month vs. commitment periods). On all three criteria, Luma Health scores as well or better than platforms with longer operating histories. Ro Body's 8-year track record is a genuine point in its favor for patients who weight platform longevity heavily — and is reflected in its #2 ranking.
Which GLP-1 provider has the best pharmacy transparency?
Luma Health and Ro Body both stand out on pharmacy transparency, though in different ways. Luma Health publicly names VialsRX (Texas State Board of Pharmacy #35264), which patients can verify independently at pharmacy.texas.gov before paying. Ro Body uses its own integrated pharmacy facilities — a different model of transparency that reflects direct operational control rather than a publicly named third-party partner. Both approaches provide meaningful pharmacy accountability. Most other ranked providers (Hims, Found, Form Health) do not prominently disclose their specific compounding pharmacy partners in public marketing.
Why does dose-tier pricing matter in these rankings?
Dose-tier pricing — where the monthly cost increases as patients escalate from starting doses to maintenance doses — is the most common source of billing surprises in the GLP-1 telehealth market. Most patients spend 3 to 5 months titrating from 0.25 mg/week to 2.4 mg/week for semaglutide (or 2.5 mg to 15 mg for tirzepatide) and then remain at maintenance for 6 to 18+ months. The maintenance dose price, not the starting price, is what most patients will pay for most of their treatment. Providers that advertise a $79/month starting price but charge $149 to $199/month at maintenance are effectively $149 to $199/month providers for most of a patient's treatment course. Luma Health's flat rate eliminates this variable entirely.
Can I switch providers mid-treatment without restarting titration?
Yes. Switching compounded GLP-1 providers mid-treatment does not require titration restart. The active pharmaceutical ingredient is the same semaglutide or tirzepatide molecule regardless of which licensed compounding pharmacy prepared it. Your new provider prescribes at your current dose based on your documented treatment history. The practical sequence: complete the new provider's intake while you still have 2 to 3 weeks of medication remaining, wait for shipping confirmation from your new provider, then cancel your current subscription. Inject at your next scheduled weekly dose from your new medication without any gap or clinical adjustment.
Do all top GLP-1 providers offer tirzepatide?
Not all ranked providers offer tirzepatide as a consistently available core option. Luma Health offers compounded tirzepatide at $297/month flat across all dose tiers from 2.5 mg to 15 mg, consistently available in all 50 states. Ro Body offers tirzepatide with dose-tier pricing ($329–$399/month at maintenance) and also provides insurance coordination for brand-name Zepbound. Hims' tirzepatide availability should be verified directly. Form Health's tirzepatide availability varies and should be confirmed before enrolling. Found's tirzepatide access varies by plan. If tirzepatide access is important to your treatment plan, Luma Health and Ro Body are the most reliable options among the top five.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes (SELECT). N Engl J Med. 2023;389:2221–2232. PubMed
- American Board of Obesity Medicine. ABOM Certification. abom.org
- FDA. Human Drug Compounding — Section 503A. FDA.gov
- NABP. Compounding Pharmacy Accreditation. nabp.pharmacy
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov
- FDA. Wegovy (semaglutide) Prescribing Information. FDA.gov